Breast Cancer Archives | VJOncology

The Breast Cancer Channel on VJOncology is supported by Gilead. These supporters have no influence over the production of the content.

View overview page

What to look forward to in breast cancer at ASCO 2023

Hope Rugo • 12 May 2023

HER2DX risk-score in early-stage HER2-positive breast cancer

Guillermo Villacampa Javierre • 12 May 2023

Detailed safety analysis from the DESTINY-Breast04 trial

Hope Rugo • 12 May 2023

Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer

Patrick Neven • 11 May 2023

KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs

Hope Rugo • 12 May 2023

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Patrick Neven • 11 May 2023

Biopsy analyses from the TALAVE trial of induction talazoparib

Filipa Lynce • 17 Apr 2023

TALAVE: induction talazoparib with PARP inhibition in breast cancer

Filipa Lynce • 17 Apr 2023

JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitors

Timothy Yap • 13 Mar 2023

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer

Eva Ciruelos • 16 Mar 2023

Oncoplastic breast conservation vs nipple sparing mastectomy & immediate breast reconstruction

Eirini Angelidou • 17 Mar 2023

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Eva Ciruelos • 16 Mar 2023

Optimal neoadjuvant and adjuvant therapy for patients with early TNBC

Hope S. Rugo • 17 Mar 2023

De-escalation of radiation therapy after primary systemic therapy in non-metastatic breast cancer

Icro Meattini • 16 Mar 2023

Important considerations in the management of HR+, HER2-negative early breast cancer

Sara Tolaney • 17 Mar 2023

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Eva Ciruelos • 16 Mar 2023

1
2
3
4
5
…
26
Next